Drugs / Wharton's jelly-derived mesenchymal cells
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT04011059 Comparator | Jul 2019 → Jan 2022 | coronary artery disorder, heart failure | Hospital San Vicente Fundación | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Wharton's jelly-derived mesenchymal cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04011059 ↗ |
| Known as | WJ-MSCs | “we aim to determine the effect of therapy using Wharton's jelly-derived mesenchymal cells (WJ-MSCs) from the human umbilical cord on neomyogenesis in patients with previous...” NCT04011059 ↗ |
| Route | Other | “intramyocardial injection of WJ-MSCs” NCT04011059 ↗ |